FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Huh Hoyoung
   2. Issuer Name and Ticker or Trading Symbol
AntriaBio, Inc. [ANTB] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last)
(First)
(Middle)
890 SANTA CRUZ AVENUE		 3. Date of Earliest Transaction (Month/Day/Year)
03/26/2014
(Street)

MENLO PARK, CA 94025		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/31/2014   A   1,057,693 (1) (2) A $ 275,000 5,057,693 (1) I By Konus Advisory Group, Inc. (1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Warrant to purchase common stock $ 1.25 03/31/2016   J(3)   234,700   03/31/2014 03/31/2019 Common Stock 234,700 (3) 234,700 I By Konus Advisory Group, Inc. (1)

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Huh Hoyoung
890 SANTA CRUZ AVENUE
MENLO PARK, CA 94025		   X   X    

Signatures

 /s/ Hoyoung Huh   04/09/2014
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Konus Advisory Group, Inc. owns 5,057, 693 shares of common stock of the Issuer. Mr. Elam and Dr. Hoyoung Huh are significant stockholders, managing members and members of the board of directors of Konus Advisory Group, Inc. Mr. Elam and Dr. Huh share voting and dispositive power of the shares of the Issuer's common stock held by Konus Advisory Group, Inc.
(2) On March 26, 2014, AntriaBio, Inc. (the "Company" or "AntriaBio, Inc.") entered into a repayment agreement (the "Repayment Agreement") with Konus Advisory Group, Inc. ("Konus"). Pursuant to the terms of the Repayment Agreement, AntriaBio, Inc. agreed to repay to Konus $1,182,644, representing the total amounts due and owing to Konus for services rendered by Konus and its consultants to the Company (the "Balance") as set forth in the Konus Agreements (as defined in the Repayment Agreement) through, (i) the issuance of $275,000 worth of shares of our common stock (the "Payment Shares") with such Payment Shares to be valued at $0.26 per share and (ii) a cash payment or series of cash payments totaling $907,644 to be paid at such time as mutually agreed to by Konus and the Company.
(3) As set forth on the Company's Current Report on Form 8-K filed with the SEC on November 15, 2013, on November 14, 2013, the Company issued a 14% promissory note in the principal amount of $250,000 (the "Konus Note") to Konus in order to evidence funds Konus loaned to the Company. Pursuant to the terms of the Konus Note, the principal balance of the Note is due at the earlier of, (i) November 1, 2014 or (ii) ten days after the closing of an equity financing that raises at least three million dollars. As set forth in Item 1.01 of the Company's Current Report on Form 8-K filed with the SEC on April 1, 2014, on March 31, 2014, the Company completed an initial close of an equity financing for aggregate proceeds of approximately $5 million. As a result, the Company agreed to pay the outstanding principal and interest on the Konus Note within ten (10) days after the closing of the PIPE Financing and we agreed to issue to Konus a warrant (the "Konus Warrant") to purchase 234,700 shares of

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.